RxDoctor Payments Data

Sabino Velloze, MD

Cardiovascular Disease · Middleburg Heights, OHNPI 1427084870

Payments from drug & device makers

$47,203in general payments, 2019–2025

Across 105 payments — averaging $449.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Esperion Therapeutics, Inc.$46K
  • E.r. Squibb & Sons, L.L.C.$493
  • Medtronic$253
  • Abbott$124
  • Astellas Pharma US Inc$99
  • Alnylam Pharmaceuticals Inc.$95
  • plus $156 from 6 others

What the payments were for

  • Food & beverage$1,12292%
  • Education$998%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$47,203 in reported general payments places this provider in the 85th percentile of 827 cardiovascular disease providers in Ohio.

See all cardiovascular disease providers in Ohio

Medicare billing

Part B allowed, 2024
$147,229
Medicare patients
824
Services billed
2,106

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban495$578,541
XareltoRivaroxaban267$314,912
VyndamaxTafamidis11$255,289
CamzyosMavacamten12$100,706
EntrestoSacubitril/Valsartan72$87,783
Repatha SureclickEvolocumab31$24,773
FarxigaDapagliflozin Propanediol22$20,260
Metoprolol Succinate1,101$19,352
VascepaIcosapent Ethyl14$10,828
Ezetimibe400$8,207
Colesevelam Hcl16$6,479
Atorvastatin Calcium612$5,762
Digoxin161$5,028
Rosuvastatin Calcium398$4,874
ClopidogrelClopidogrel Bisulfate242$2,799

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Vyndamax$18$833,830506 claims
E.r. Squibb & Sons, L.L.C.Camzyos$493$100,70612 claims
NovartisEntresto$29$87,78372 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 827 cardiovascular disease providers in Ohio.

Other cardiovascular disease in Middleburg Heights

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →